Petros Pharmaceuticals, Inc. (PTPI) Stock Analysis & Investment Frameworks
Petros Pharmaceuticals, Inc. (PTPI) stock analysis on Invetso. Review Petros Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Petros Pharmaceuticals, Inc. Company Overview
- Exchange: Other OTC
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
Petros Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $127117.00
- Revenue: $N/A
- P/E Ratio: 0.06
- ROE: -147.02%
- ROIC: -484.80%
- Dividend Yield: N/A
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.